Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Begoña Porta-Oltra"'
Autor:
Sara Giménez-Giner, Antoni Llopis-Alemany, Begoña Porta-Oltra, Pilar Llopis-Salvia, Mónica Climente-Martí, María Amparo Martínez-Gómez
Publikováno v:
Enfermedades infecciosas y microbiologia clinica (English ed.).
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 45(7)
Indication of personalized pharmacotherapy in oncologic patients is based on the selection of the optimal treatment (drugs, dosing, routes and methods of administration and duration) and on the most appropriate dosing method to achieve maximum antine
Autor:
Beatriz Guglieri-López, Mónica Climente-Martí, Alejandro Pérez-Pitarch, Matilde Merino-Sanjuán, Dirk Jan A.R. Moes, Begoña Porta-Oltra, Henk-Jan Guchelaar
Publikováno v:
CANCER CHEMOTH PHARM
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Cancer Chemotherapy and Pharmacology, 79(1), 189-200
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Cancer Chemotherapy and Pharmacology, 79(1), 189-200
Lenalidomide disease-specific toxicity profiles and potentially life-threatening adverse events support the consideration of diversity in starting doses. The aim of this study was to conduct a population pharmacokinetic analysis of lenalidomide in mu
Autor:
Ángeles Royo-Peiró, Beatriz Guglieri-López, Mónica Climente-Martí, Francisco Ferriols-Lisart, Begoña Porta Oltra, Alejandro Pérez-Pitarch
Publikováno v:
Anti-cancer drugs. 27(7)
To evaluate the effectiveness and toxicity profile of ipilimumab treatment and to examine the cost-effectiveness relation in a real-world sample of patients with metastasic melanoma. This was a multicenter, observational, retrospective cohorts study.
Autor:
Begoña Porta-Oltra, Joaquim Monteiro, Matilde Merino-Sanjuán, N. Víctor Jiménez-Torres, I. Maestu, D. Almenar
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 109:457-464
The aim of this study was to evaluate systemic exposure to carboplatin and its haematological toxicity in patients with advanced non-small cell lung cancer both older and younger than 70 years when the target area under the curve (AUC) in elderly pat
Autor:
Elena Gras Colomer, Begoña Porta Oltra, Mónica Climente Martí, María Amparo Martínez Gómez, Ana Moya Gil
Publikováno v:
Journal of Analytical & Bioanalytical Techniques. 7
The use of a combination of 5HT3 receptor antagonist, a NK-1 receptor antagonist and dexamethasone has been classified to be state of the art in patients receiving highly as well as moderately emetogenic chemotherapy like cisplatin and anthracyclines
Autor:
Mónica Climente-Martí, Matilde Merino-Sanjuán, María Amparo Martínez-Gómez, Alejandro Pérez-Pitarch, Beatriz Guglieri-López, Begoña Porta-Oltra
Publikováno v:
Journal of laboratory automation. 21(6)
A wide linearity range analytical method for the determination of lenalidomide in patients with multiple myeloma for pharmacokinetic studies is required. Plasma samples were ultrasonicated for protein precipitation. A solid-phase extraction was perfo
Autor:
Gustavo, Camps-Valls, Begoña, Porta-Oltra, Emilio, Soria-Olivas, José David, Martín-Guerrero, Antonio José, Serrano-López, Juan José, Pérez-Ruixo, Nicolás Víctor, Jiménez-Torres
Publikováno v:
IEEE Transactions on Biomedical Engineering. 50:442-448
This paper proposes the use of neural networks for individualizing the dosage of cyclosporine A (CyA) in patients who have undergone kidney transplantation. Since the dosing of CyA usually requires intensive therapeutic drug monitoring, the accurate
Publikováno v:
Journal of Analytical & Bioanalytical Techniques. 5
Fosaprepitant dimeglumine is a new drug indicated to prevent nausea and vomiting associated with highly emetogenic cisplatin-based and moderately emetogenic cancer chemotherapy in adults. Due to its complexity in managing, since it requires reconstit